<DOC>
	<DOCNO>NCT01595997</DOCNO>
	<brief_summary>The overall purpose study support development DLX105 topical formulation indication mild moderate psoriasis vulgaris .</brief_summary>
	<brief_title>Intra-dermal Injections DLX105 Into Lesional Skin Patients With Mild-to-moderate Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed date Informed Consent Male female Caucasian patient stable chronic mildtomoderate plaquetype psoriasis ( PASI ≤15 ) age 1875 year must least two pronounced active lesion &gt; 9 cm2 , stable least 3 month , local PASI score ≥8 . Distance lesion must least 30 cm . Affected body surface area ( BSA ) ≤10 % Negative pregnancy test females child bear potential ( premenopausal , &lt; 2 year postmenopausal , surgically sterile ) Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttate psoriasis , palmar , plantar nail disease ) screening Druginduced psoriasis ( i.e. , new onset current exacerbation betablockers , calcium channel inhibitor lithium ) prior randomization Ongoing use psoriasis treatment ( duration washout , i.e . discontinuation prior randomization ) : Alefacept ( 6 month ) Biological agent alefacept , e.g . adalimumab , efalizumab , etanercept , infliximab , ustekinumab ( 12 week ) Systemic therapy psoriasis psoriatic arthritis ( ) e.g . methotrexate , cyclosporin , fumaric acid ( derivative ) , systemic steroid ( 4 week ) Photochemotherapy e.g. , ultraviolet A psoralen ( PUVA ) ( 4 week ) Phototherapy e.g. , ultraviolet A ( UVA ) ultraviolet B ( UVB ) ( 2 week ) Topical treatment , except face , scalp genital area screening ( 2 week ) Other investigational psoriasis drug ( 4 week 5 halflives , whichever long ) Ongoing use ( nonpsoriasis ) treatment ( duration washout , i.e . discontinuation prior randomization ) : Investigational drug , psoriasis drug ( 4 week 5 halflives , whichever long ) Known immunosuppression History evidence active tuberculosis . All patient test tuberculosis status use blood test ( QuantiFERON TBGold ) unless test perform within 4 month prior randomization negative . Patients evidence latent tuberculosis may enter trial sufficient treatment initiate accord local regulation . Active systemic infection ( common cold ) two week randomization Positive test hepatitis B C screen Positive test HIV screen History symptom malignancy organ system ( history basal cell carcinoma / three squamous cell carcinoma skin , successful treatment perform , sign recurrence ; actinic keratoses , present screening , treat accord standard therapy randomization ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . History severe hypersensitivity human humanize biological agent Any severe , progressive uncontrolled medical condition baseline judgment investigator prevents patient participate study Any clinically significant abnormal laboratory test baseline Active liver disease alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal History moderate severe congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) . Inability unwillingness undergo repeat venipuncture ( e.g. , due poor tolerability lack access vein ) History evidence drug alcohol abuse within 6 month prior first study drug administration Patients live vaccination within 6 week prior first study drug administration , require live vaccination course trial History hypersensitivity excipients study drug excipients similar chemical class History hypersensitivity active ingredient similar chemical entity ( polypeptide ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin ( HCG ) laboratory test ( &gt; 5 mIU/mL ) Women childbearing potential , defined woman physiologically capable become pregnant . UNLESS Women whose partner sterilize vasectomy mean Using highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , condom ( partner ) , intrauterine device ( IUDs ) ) . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal consider acceptable form birth control within study . Reliable contraception maintain throughout study 12 week last study drug administration Participation clinical trial within 4 week prior trial Exposure DLX105 / ESBA105 previous study antibody fragment Part A study ( i.e . patient participate Part A B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>safety tolerability immunogenicity two different dos DLX105 apply intra-dermally psoriatic lesion mild-to-moderate psoriatic patient</keyword>
</DOC>